The Bengaluru-based company uses AI-led discovery to search for small molecules that act on the same receptors as injectable GLP-1 drugs, aiming for a cheaper alternative.
Obesity drugs that changed the field are peptides, and peptides are injected.
They need cold storage, are expensive to manufacture, and the supply chain that carries them does not reach most of the world.
A pill that acted on the same biology would be cheaper to make and far easier to distribute.
was founded in Bengaluru in 2023 to fill this gap.
Dr Ramkesh Meena is the chief executive and Sudhir Nagarajan is the managing director.
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how…
A new startup is making a bold move in the world of obesity drug development: It’s not working with the GLP-1 target that has…
The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side…
Despite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Nithin Kamath highlights patient retention…
Drugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.
Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for…
